Business
Intensity Therapeutics Regains Compliance with Nasdaq's Minimum Bid Price Requirement
SHELTON, Conn., March 6, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology
About this update from Intensity Therapeutics, Inc.
[{"type":"text","content":"SHELTON, Conn., March 6, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. (\"Intensity\" or \"the Company\") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system recognition of cancers using its proprietary non-covalent conjugation technology, today announced that it has received formal notice from the Listings Qualifications staff of The Nasdaq Stock Market LLC (\"Nasdaq\") that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share. Nasdaq confirmed that for the last 10 consecutive business days, from February 19, 2026 through March 4, 2026, the closing bid price of the Company's common stock was at or above $1.00, and as a result, the matter is now closed.\n \n \n \n \n \n \n \nAbout Intensity TherapeuticsIntensity is a late-stage clinical biotechnology company whose novel engineered chemistry enables aqueous cytotoxic-containing drug formulations to mix and saturate a tumor's dense, high-fat, pressurized environment following direct intratumoral injection. As a result of the saturation, Intensity's clinical trials have demonstrated the ability of INT230-6 to kill tumors and elicit an adaptive immune response within days of injection, representing a new approach to cancer cell death that holds the potential to shift the treatment paradigm and turn many deadly cancers into chronic diseases even for malignancies that do not respond to conventional immunotherapy. Intensity has completed two clinical studies and enrolled over 200 patients using INT230-6; a Phase 1/2 dose escalation study in metastatic cancers including sarcomas (NCT03058289), and a Phase 2 randomized control clinical trial in locally advanced breast cancer (the \"INVINCIBLE-2 Study\") (NCT04781725) in women without undergoing chemotherapy prior to their surgery. The Company initiated a Phase 3 trial in soft tissue sarcoma (the \"INVINCIBLE-3 Study\") (NCT06263231), testing INT230-6 as second or third line monotherapy compared to the standard of care (\"SOC\") with overall survival as an endpoint. Intensity also initiated a Phase 2 study (the \"INVINCIBLE-4 Study\") (NCT06358573) in collaboration with the Swiss Cancer Group, formerly the Swiss Grou...